Skip to main content
    B

    Beta Bionics, Inc. Common Stock (BBNX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $17.31
    +0.44 (+2.61%)

    Market Cap: $910.07M

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    71%(5/7)
    Avg Surprise
    -12.61%
    Streak
    5 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.49
    Range$-0.53 - $-0.46
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.53+6.0%
    60d ago$-0.53+6.0%
    30d ago$-0.51+2.9%
    7d ago$-0.51+2.9%
    Current$-0.49
    Revenue Consensus
    $35M
    Range$34M - $36M
    12 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.33
    Range$-0.55 - $-0.10
    2 analysts
    Revenue Consensus
    $33M
    Range$29M - $42M
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.33---
    Sep 26EST
    		-$-0.49---
    Jun 26
    Reported Jul 29
    		$-0.53$-0.62+14.52%Beat-96.3%
    Mar 26
    Reported Apr 21
    		$-0.36$-0.45+20.00%Beat+61.3%
    Dec 25
    Reported Feb 17
    		$-0.30$-0.38+21.05%Beat+89.0%
    Sep 25
    Reported Oct 28
    		$-0.33$-0.41+19.51%Beat+59.8%
    Jun 25
    Reported Jul 29
    		$-0.27$-0.47+42.55%Beat-
    Mar 25
    Reported May 6
    		$-0.93$-0.51-82.35%Miss-
    Dec 24
    Reported Jan 31
    		$-2.72$-1.22-123.56%Miss-
    Sep 24
    Reported Nov 27
    		$-0.82$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-11.39EV/EBITDAN/A
    Price/FCF-12.56xFCF Yield-7.96%
    Profitability
    Profit Margin-61.30%Operating Margin-79.90%
    ROE-26.20%ROIC-25.10%
    Financial Health
    Debt/Equity0.02xInterest CoverageN/A
    Current Ratio8.88xQuick Ratio7.96x
    Trading Statistics
    BetaN/AAvg Volume1.42M
    52-Week High$32.7152-Week Low$8.80

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$17.94
    SMA 20$19.47
    SMA 50$18.93
    SMA 200$15.25
    EMA 10$17.97
    EMA 20$18.59
    EMA 50$18.41
    EMA 200$16.79

    MACD

    Line: -0.56Signal: -0.22Hist: -0.34

    ADX

    ADX: 20.7+DI: 16.7-DI: 27.1

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down8.0
    PSAR$19.90

    Bollinger Bands

    Upper Band$23.31
    Lower Band$15.63
    %B Position3944%(Upper)
    Band Width0.22

    RSI (14-Day)

    Neutral
    39.6

    Momentum Oscillators

    Stoch %K9.3
    Stoch %D9.6
    Williams %R-86.1
    ROC (10d)-8.3%
    Momentum-1.56
    CCI (20d)-94.8
    MFI (14d)24.6

    Volatility Measures

    ATR (14d)$1.13(6.6%)
    StdDev (20d)1.92
    Hist Vol40.1%(High)

    Volume Flow

    VWAP$17.17
    OBV-27.3M
    AD Line3.8M
    CMF (20d)-0.214

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio1.3x
    VWMA (20d)$19.57

    Pivot Points

    R3$18.19
    R2$17.86
    R1$17.37
    Pivot Point$17.04
    S1$16.55
    S2$16.22
    S3$15.73

    Advanced Oscillators

    TSI-13.68
    Ultimate Osc37.6
    KST-59.97

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$32.01M$27.63M$32.12M$27.25M$23.24M$17.64M$20.44M$16.70M$15.05M$12.93M$8.35M$3.09M
    Cost of Revenue$13.11M$11.19M$13.18M$12.13M$10.73M$8.67M$8.75M$7.79M$6.96M$5.73M$3.29M$1.87M
    Gross Profit$18.90M$16.44M$18.94M$15.12M$12.50M$8.97M$11.69M$8.91M$8.08M$7.20M$5.06M$1.23M
    Operating Expenses$44.48M$40.71M$35.07M$32.16M$32.38M$27.61M$24.73M$19.89M$19.87M$16.65M$13.43M$10.01M
    R&D$10.24M$10.36M$10.13M$8.20M$8.87M$7.59M$9.21M$5.14M$6.35M$5.48M$4.46M$3.85M
    SG&A$9.60M$9.62M$8.60M$7.92M$7.88M$6.62M$4.71M$5.11M$4.54M$3.51M$3.35M$2.83M
    Operating Income$-25,578,000$-24,271,000$-16,124,000$-17,043,000$-19,872,000$-18,642,000$-13,037,000$-10,977,000$-11,784,000$-9,453,000$-8,367,000$-8,782,000
    Interest Income$2.18M$2.38M$2.66M$2.83M$3.00M$2.44M$951,000$826,000$993,000$1.14M$1.25M$0
    Interest Expense$0$0$0$0$0$10.01M$5.07M$0$2.68M$3.00M$55,000$0
    Income Before Tax$-23,401,000$-21,895,000$-13,465,000$-14,209,000$-16,869,000$-28,656,000$-18,106,000$-9,736,000$-14,463,000$-12,449,000$-18,848,000$-8,680,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-23,403,000$-21,895,000$-13,466,000$-14,209,000$-16,869,000$-28,656,000$-18,108,000$-9,736,000$-14,463,000$-12,449,000$-18,848,000$-8,680,000
    EBITDA$-24,365,000$-23,198,000$-15,125,000$-16,359,000$-20,035,000$-31,404,000$-18,528,000$-9,947,000$-14,880,000$-13,025,000$-18,556,000$-8,368,667
    EBIT$-25,578,000$-24,271,000$-16,123,000$-17,042,000$-19,874,000$-31,092,000$-19,057,000$-10,562,000$-15,456,000$-13,588,000$-18,848,000$-8,680,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BBNX

    News

    Kaplan Fox Advises Investors of Beta Bionics, Inc. (NASDAQ: BBNX) of an Upcoming Securities Class Action Deadline on November 3, 2026

    Kaplan Fox & Kilsheimer LLP has announced a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased stock between July 30, 2025, and February 24...

    The National Law Review•10/15/26•Bearish

    Beta Bionics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Beta Bionics, Inc. - BBNX

    ClaimsFiler is reminding Beta Bionics (NasdaqGM: BBNX) investors with losses over $100,000 that they have until November 3, 2026...

    GlobeNewswire•10/15/26•Bearish

    BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit

    Schall, Brown & Schwartz LLP has filed a federal securities class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased common stock between July 30, 2025, and February 24...

    WBOC TV•10/15/26•Bearish

    SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 3, 2026 in Beta Bionics, Inc. Lawsuit - BBNX

    SueWallSt is reminding shareholders of Beta Bionics, Inc. (NASDAQ: BBNX) that a lead plaintiff deadline of November 3, 2026...

    PR Newswire•10/15/26•Bearish

    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BBNX

    Pomerantz LLP has announced a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX), urging investors who suffered losses to come forward by the November 3...

    PR Newswire•10/15/26•Bearish

    BBNX Valuation and Fair Value

    P/E
    -11.4x
    P/FCF
    -12.6x
    P/B
    3.0x
    See GNG's fair value

    BBNX Profitability: Margins, ROIC and FCF

    Gross margin
    58.3%
    Operating margin
    -79.9%
    Net margin
    -61.3%
    ROIC
    -25.1%
    ROE
    -26.2%
    FCF margin
    -51.6%
    FCF yield
    -8.0%

    BBNX Competitors

    CompanyTicker
    Quidel CorporationQDEL
    Theravance Biopharma IncTBPH
    MannKind CorpMNKD
    MoonLake ImmunotherapeuticsMLTX
    Savara IncSVRA
    Rigel Pharmaceuticals IncRIGL
    Ventyx Biosciences IncVTYX
    Kura Oncology IncKURA

    Sector: Healthcare

    BBNX Analyst Ratings

    Consensus
    Buy
    Analysts
    13
    Strong Buy
    1
    Buy
    8
    Hold
    4
    Sell
    0
    Strong Sell
    0

    BBNX Bull Case vs Bear Case

    Bull case

    • BBNX grew quarterly revenue 37.8% year over year.
    • 69.2% of BBNX's analyst ratings are Buy or Strong Buy.

    Bear case

    • BBNX has a -61.3% net profit margin.

    BBNX Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    -12.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.49
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About BBNX

    Does BBNX pay dividends?

    Beta Bionics, Inc. Common Stock (BBNX) does not currently pay a regular dividend.

    What is BBNX's market cap?

    Beta Bionics, Inc. Common Stock (BBNX) has a market capitalization of $910.07M with a current stock price of $17.31.

    Related stocks

    Sector: Healthcare

    All stocks starting with B

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In